These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26113417)

  • 1. Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease.
    Nabhani S; Ginzel S; Miskin H; Revel-Vilk S; Harlev D; Fleckenstein B; Hönscheid A; Oommen PT; Kuhlen M; Thiele R; Laws HJ; Borkhardt A; Stepensky P; Fischer U
    Haematologica; 2015 Sep; 100(9):1189-98. PubMed ID: 26113417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation.
    Martínez-Feito A; Melero J; Mora-Díaz S; Rodríguez-Vigil C; Elduayen R; González-Granado LI; Pérez-Méndez D; Sánchez-Zapardiel E; Ruiz-García R; Menchén M; Díaz-Madroñero J; Paz-Artal E; Del Orbe-Barreto R; Riñón M; Allende LM
    Immunobiology; 2016 Jan; 221(1):40-7. PubMed ID: 26323380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome.
    Nabhani S; Hönscheid A; Oommen PT; Fleckenstein B; Schaper J; Kuhlen M; Laws HJ; Borkhardt A; Fischer U
    Clin Immunol; 2014 Dec; 155(2):231-7. PubMed ID: 25451160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.
    Magerus-Chatinet A; Stolzenberg MC; Lanzarotti N; Neven B; Daussy C; Picard C; Neveux N; Desai M; Rao M; Ghosh K; Madkaikar M; Fischer A; Rieux-Laucat F
    J Allergy Clin Immunol; 2013 Feb; 131(2):486-90. PubMed ID: 22857792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats.
    Aberdein D; Munday JS; Gandolfi B; Dittmer KE; Malik R; Garrick DJ; Lyons LA;
    Mamm Genome; 2017 Feb; 28(1-2):47-55. PubMed ID: 27770190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FcRγ promotes T cell apoptosis in Fas-deficient mice.
    Juvet SC; Thomson CW; Kim EY; Joe B; Adeyi O; Zhang L
    J Autoimmun; 2013 May; 42():80-93. PubMed ID: 23313147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
    Ruiz-García R; Mora S; Lozano-Sánchez G; Martínez-Lostao L; Paz-Artal E; Ruiz-Contreras J; Anel A; González-Granado LI; Moreno-Pérez D; Allende LM
    Pediatr Res; 2015 Dec; 78(6):603-8. PubMed ID: 26334989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAS-mediated apoptosis impairment in patients with ALPS/ALPS-like phenotype carrying variants on CASP10 gene.
    Miano M; Cappelli E; Pezzulla A; Venè R; Grossi A; Terranova P; Palmisani E; Maggiore R; Guardo D; Lanza T; Calvillo M; Micalizzi C; Pierri F; Vernarecci C; Beccaria A; Corsolini F; Lanciotti M; Russo G; Ceccherini I; Dufour C; Fioredda F
    Br J Haematol; 2019 Nov; 187(4):502-508. PubMed ID: 31309545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).
    Marega LF; Teocchi MA; Dos Santos Vilela MM
    Clin Exp Immunol; 2016 Aug; 185(2):148-53. PubMed ID: 27060458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
    Hsu AP; Dowdell KC; Davis J; Niemela JE; Anderson SM; Shaw PA; Rao VK; Puck JM
    Genet Med; 2012 Jan; 14(1):81-9. PubMed ID: 22237435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
    Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
    J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation.
    Revel-Vilk S; Fischer U; Keller B; Nabhani S; Gámez-Díaz L; Rensing-Ehl A; Gombert M; Hönscheid A; Saleh H; Shaag A; Borkhardt A; Grimbacher B; Warnatz K; Elpeleg O; Stepensky P
    Clin Immunol; 2015 Jul; 159(1):84-92. PubMed ID: 25931386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
    Rieux-Laucat F; Magérus-Chatinet A; Neven B
    J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype.
    Boggio E; Aricò M; Melensi M; Dianzani I; Ramenghi U; Dianzani U; Chiocchetti A
    Pediatrics; 2013 Oct; 132(4):e1052-8. PubMed ID: 24043286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
    Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
    BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation Sequencing for Detecting Somatic
    López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
    Front Immunol; 2021; 12():656356. PubMed ID: 33995372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.
    Dowdell KC; Niemela JE; Price S; Davis J; Hornung RL; Oliveira JB; Puck JM; Jaffe ES; Pittaluga S; Cohen JI; Fleisher TA; Rao VK
    Blood; 2010 Jun; 115(25):5164-9. PubMed ID: 20360470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-malignant, non-infectious lymphoproliferation: challenges in the diagnosis and treatment of autoimmune lymphoproliferative syndrome].
    Molnár E; Kovács G; Varga L; Tasnády S; Bors A; Tankó L; Csabán D; Kapócs K; Nemes-Nagy Z; Andrikovics H
    Orv Hetil; 2022 Jan; 163(4):123-131. PubMed ID: 35066491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds.
    Nabhani S; Schipp C; Miskin H; Levin C; Postovsky S; Dujovny T; Koren A; Harlev D; Bis AM; Auer F; Keller B; Warnatz K; Gombert M; Ginzel S; Borkhardt A; Stepensky P; Fischer U
    Clin Immunol; 2017 Aug; 181():32-42. PubMed ID: 28579554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.